Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.55 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | PARP1 | P09874 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15163681 | 0.90 | L3MBTL3 (0.49) | L3MBTL1L3MBTL3ALDH1A1HPGDKDM4E | |
| SCHEMBL13373550 | 0.85 | HPGD (0.58) | L3MBTL1ALDH1A1HPGDKDM4EPOLB | |
| SCHEMBL29565081 | 0.83 | HPGD (0.61) | L3MBTL1ALDH1A1HPGDKDM4EPOLB | |
| SCHEMBL1855879 | 0.83 | HPGD (0.61) | L3MBTL1ALDH1A1HPGDKDM4EPOLB | |
| SCHEMBL1855882 | 0.83 | HPGD (0.61) | L3MBTL1ALDH1A1HPGDKDM4EPOLB | |
| SCHEMBL3153203 | 0.81 | SMN1; SMN2 (0.57) | L3MBTL1ALDH1A1HPGDKDM4EPOLB | |
| SCHEMBL1063453 | 0.81 | L3MBTL1 (0.57) | L3MBTL1ALDH1A1HPGDKDM4EHTT | |
| SCHEMBL13646643 | 0.81 | SMN1; SMN2 (0.60) | L3MBTL1ALDH1A1HPGDKDM4EPOLB | |
| SCHEMBL1063794 | 0.80 | SMN1; SMN2 (0.59) | L3MBTL1ALDH1A1HPGDKDM4EPOLB | |
| SCHEMBL424249 | 0.80 | L3MBTL1 (0.54) | L3MBTL1L3MBTL3ALDH1A1KDM4EPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118057-A1 | (INDOL-4-YL)- OR (INDOL-5-YL)-PIPERAZINYLMETHANONE DERIVATIVES FOR THE TREATMENT OF OBESITY | F. Hoffmann-Roche AG (CH) | 2009-11-18 | — | — | EP | disclosed |
| US-7557108-B2 | (Indol-4-yl) or (indol-5-yl)-piperazinylmethanones | HOFFMANN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557108-B2 | (Indol-4-yl) or (indol-5-yl)-piperazinylmethanones | HOFFMANN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557108-B2 | (Indol-4-yl) or (indol-5-yl)-piperazinylmethanones | HOFFMANN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| WO-2008095820-A1 | (INDOL-4-YL)- OR (INDOL-5-YL)-PIPERAZINYLMETHANONE DERIVATIVES FOR THE TREATMENT OF OBESITY | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-14 | — | — | WO | disclosed |
| US-20080188486-A1 | (INDOL-4-YL) OR (INDOL-5-YL)-PIPERAZINYLMETHANONES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-07 | — | — | US | disclosed |
| US-20080188486-A1 | (INDOL-4-YL) OR (INDOL-5-YL)-PIPERAZINYLMETHANONES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-07 | — | — | US | disclosed |
| US-20080188486-A1 | (INDOL-4-YL) OR (INDOL-5-YL)-PIPERAZINYLMETHANONES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188486-A1 | (INDOL-4-YL) OR (INDOL-5-YL)-PIPERAZINYLMETHANONES | HRH4, HRH3, H1-3 | L3MBTL1 2317/4885L3MBTL3 1921/4885ALDH1A1 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.